AI Drug Discovery & Development Summit 2026

Biointron is excited to participate in the 5th Annual AI Drug Discovery & Development Summit, taking place October 27–29, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts. 

As artificial intelligence moves from exploratory research into active drug discovery and development pipelines, access to reliable experimental data is becoming increasingly important. The summit will convene more than 1,000 industry leaders and innovators to share practical experience implementing AI across the pharmaceutical value chain—from target identification and molecular design to clinical development and technical operations. 

The 2026 program will feature six content tracks covering discovery biology, discovery chemistry, data, high-performance computing and AI infrastructure, clinical trials, and technical operations. Attendees can also participate in scientific poster presentations, start-up showcases, and curated one-to-one meetings designed to connect technology developers with pharmaceutical and biotechnology organizations. 

At Biointron, we help AI-driven antibody developers translate computational designs into actionable experimental results. Our integrated gene-to-data capabilities combine high-throughput CHO expression with affinity and developability characterization, generating structured wet-lab datasets for candidate evaluation and model iteration. 

Meet the Biointron team in Boston to discuss how rapid, scalable antibody testing can strengthen the connection between computational design and experimental validation. We look forward to learning about your programs and exploring how better wet-lab data can support faster, evidence-based antibody development. 

For more details about the event, please visit the AIDDD 2026 website [https://www.aidrivendrugdevelopment.com/] 

Time: October 27 – 29, 2026 

Location: Boston Marriott Copley Place | Boston, MA 

Booth: TBD